News & Events

  • Title : Hallym to collaborate with Biosolution for regenerative medicine research
No. :
Date :
Hit :


  • Hallym University Medical Convergence Center (HUMCC) concluded an MOU with Biosolution, a leading company in Cell-based biotechnology, on cutting-edge regenerative medicine research and related drug development at Hallym University Hangang Sacred Heart Hospital on September 15, 2020.

    The MOU is designed to promote joint regenerative medicine research and new drug development in various medical fields such as inhalation burn, ligament damage, corneal damage, retinal disease, Parkinson’s disease, and immune anticancer agent.

    Based on the MOU, HUMCC will provide Biosolution with clinical infrastructures including biobank of Hallym for joint research while Biosolution will share intellectual property rights and research infrastructures related to cell regeneration therapy based on exosomes.

    The partnership is particularly meaningful to Hallym, because this is the first case where a medical institution has participated in the process of new drug development since the ‘Advanced Regenerative Medicine and Biopharmaceutical Safety and Support Act’ took effect last month. The new act allowed medical institutions to involve directly into the new drug development process.

    “The research collaboration based on the MOU will play a very important role in finding innovative therapies and approaches for rare diseases,” said HUMCC Director Wook Chun.

    “We will be able to create great synergy in research if we put our advanced regenerative medical technologies and Hallym’s extensive clinical infrastructures together,” said President Jung-Sun Lee of Biosolution.

    Hallym University Medical Convergence Center (HUMCC) was established by Hallym University Medical Center on September 1 this year for researches on future medicine. It aims at developing new medical technologies by converging medical science and the advanced technologies of the 4th industrial revolution. The fields of research include stem cell, regenerative medicine, information and communication technology, health care, and robotics.

    By Jonghun Im, Int’l Cooperation Team, HUMC (